

## MET

### Research Grade Telisotuzumab vedotin (ADC)

<b>Catalog No.</b>	DHC34299A DHC34299B	<b>Quantity:</b>	100 µg 1.0 mg
<b>Alternate Names:</b>	ABBV-399, Teliso-V, antibody-drug conjugate (ADC)		
<b>Description:</b>	Telisotuzumab vedotin is an ADC consisting of a cMET-directed antibody and Monomethyl auristatin E (MMAE) that has recently obtained the breakthrough therapy designation (BTD) for the treatment of patients with c-Met overexpression, advanced/metastatic wild-type (WT) epithelial growth factor receptor (EGFR) non-squamous non-small cell lung cancer (sqNSCLC) that progressed during or after platinum-based chemotherapy.		
<b>UniProt ID (target):</b>	P08581		
<b>Target:</b>	Human HGF receptor (Proto-oncogene c-Met)		
<b>Concentration:</b>	1.0 mg/ml, lot specific		
<b>Source:</b>	XtenCHO		
<b>Isotype:</b>	Human IgG1 kappa		
<b>Formulation:</b>	Liquid		
<b>Purity:</b>	> 90% by SEC		
<b>Endotoxin Level:</b>	≤ 0.01 EU/µg by LAL analysis		
<b>Purification:</b>	Ion exchange chromatography		
<b>INN:</b>	Telisotuzumab vedotin		
<b>Applications:</b>	Functional studies		
<b>Storage &amp; Stability:</b>	Store at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. <b>Avoid freeze/thaw cycles.</b>		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.



**Cell Sciences**<sup>®</sup>  
65 Parker Street  
Unit 11  
Newburyport, MA 01950

Toll Free: 888-769-1246  
Phone: 978-572-1070  
Fax: 978-992-0298

E-mail: [info@cellsciences.com](mailto:info@cellsciences.com)  
Website: [www.cellsciences.com](http://www.cellsciences.com)